This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cubist Unveils Five-Year Strategic Goals

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the Company’s five-year strategic aspirations – Building Blocks of Growth – at its Investor Day at the NASDAQ Market Site. Cubist’s President and Chief Executive Officer Michael Bonney shared the Company’s five-year roadmap, including goals for top- and bottom-line growth, future pipeline developments, and cultural elements that will position Cubist to deliver long-term, sustainable growth.

As detailed at the Company’s Investor Day, by year-end 2017 Cubist expects to:

  • Grow global revenue to $2 billion annually;
  • Have four product candidates in late-stage clinical trials;
  • Generate $700 million in non-GAAP annual adjusted operating income; and
  • Continue to strengthen and develop the Company’s highly differentiated culture.

“Through our transformation over the past two years, Cubist has established itself as a global leader in the acute care/hospital environment. Our Building Blocks of Growth will help us build on this momentum as we look to deliver important new medicines for patients and drive long-term value for our customers and shareholders,” said Mr. Bonney. “The next five years represent an extraordinary time of opportunity for Cubist, and our entire team is excited to deliver on the Company’s very promising future.”

Grow Global Revenue to $2 Billion

Cubist plans to generate $2 billion in global annual revenue in 2017, driven largely by organic growth.

To achieve this goal, the Company expects to:

  • Drive CUBICIN® (daptomycin for injection) growth across the U.S. and around the world through its global partnerships. By year-end 2017, the Company expects CUBICIN will well-exceed $1 billion in U.S. sales alone;
  • Expand the growth of ENTEREG® (alvimopan), which is expected to approach $100 million in sales by year-end 2017;
  • Optimize its current late-stage pipeline, led by CXA-201, CB-315, and CB-5945;
  • Build out its global commercial footprint in a targeted manner; and
  • Pursue in-licensing, partnership, and/or M&A activity as part of its active, focused, and disciplined business development program.

Four New Product Candidates in Late-Stage Clinical Trials

Cubist expects to have four new product candidates in late-stage clinical trials by year-end 2017. The Company will build on its successful balance between strong internal discovery efforts and active business development, focused on potential therapies for patients in the acute care/hospital environment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs